Agoura Hills, CA, United States of America

Todd Hager

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Todd Hager

Introduction

Todd Hager is an accomplished inventor based in Agoura Hills, California. He has made significant contributions to the field of metabolic disorder treatments. His innovative approach focuses on utilizing binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists.

Latest Patents

Todd Hager holds a patent for a method of treating or ameliorating metabolic disorders. This patent specifically addresses the use of an antigen binding protein that targets the GIPR polypeptide. The method is particularly relevant for conditions such as type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, and diabetic nephropathy. The patent emphasizes the administration of the antigen binding protein in conjunction with a GLP-1 receptor agonist.

Career Highlights

Hager is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to focus on groundbreaking research in metabolic diseases. With a patent portfolio that includes 1 patent, he continues to push the boundaries of medical science.

Collaborations

Throughout his career, Todd has collaborated with notable colleagues, including Darren L Bates and Donghui Shi. These partnerships have fostered an environment of innovation and have contributed to the advancement of research in metabolic disorders.

Conclusion

Todd Hager's contributions to the field of metabolic disorder treatments exemplify the impact of innovative thinking in medicine. His work continues to inspire advancements that may improve the lives of many individuals suffering from these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…